Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 48
- 13F valueReported value at the end of Q2 2026
- $15.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ELTX, Q2 2026
No superinvestor reported holding ELTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Elicio Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 (view filing) | Jun 28, 2024 | 188 days | Venkatesan JayDirector | PPurchase | +100.0K | $2.50 | +$249.5K | –50.0K after | AmendedDerivative2 lots |
| Aug 14, 2024 (view filing)4:41 PM ET | Aug 12 | 2 days | Chudnovsky Yekaterina and 1 otherDirector, 10% Owner | PPurchase | +3.44M | $5.81 | +$20.0M | –3.44M after | Derivative |
| Jul 2, 2024 (view filing)4:30 PM ET | Jun 28 | 4 days | Chudnovsky Yekaterina and 1 otherDirector, 10% Owner | PPurchase | +3.20M | $2.50 | +$7.98M | –1.60M after | Derivative2 lots |
| Mar 20, 2024 (view filing)4:28 PM ET | Mar 19 | 1 day | Chudnovsky Yekaterina and 1 otherDirector, 10% Owner | PPurchase | +1.03M | $5.81 | +$6.00M | –1.03M after | Derivative |
| Dec 26, 2023 (view filing)4:29 PM ET | Dec 22 | 4 days | Chudnovsky Yekaterina and 1 otherDirector, 10% Owner | PPurchase | +1.21M | $5.81 | +$7.05M | +172.6%1.92M after | |
| May 27, 2022 (view filing) | Feb 9, 2021 | 472 days | Venkatesan JaySee Remarks | SSale | −159.2K | $16.00 | −$2.55M | −10.4%1.37M after | Amended |
| May 27, 2022 (view filing) | Feb 9, 2021 | 472 days | Ganzi Victor FDirector | SSale | −246.7K | $16.00 | −$3.95M | −23.1%823.1K after | Amended |
| May 27, 2022 (view filing) | May 25 | 2 days | Venkatesan JaySee Remarks | PPurchase | +11.3K | $1.25 | +$14.1K | +0.6%1.89M after | |
| May 25, 2022 (view filing) | May 20-24 | 5 daysLate | Venkatesan JaySee Remarks | PPurchase | +82.2K | $1.23 | +$101.4K | +5.0%1.72M after | 2 lots |
| May 23, 2022 (view filing) | May 19-20 | 4 days | Nissenson AllenDirector | PPurchase | +9.38K | $1.16 | +$10.9K | New position9.38K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Elicio Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 1,211,957 | $4.74M | 2.21% | +581,042+92.1% | Added |
| BlackRock, Inc. | 766,005 | $3.00M | 0.00% | +715,408+1,413.9% | Added |
| Vanguard Capital Management LLC | 572,151 | $2.24M | 0.00% | +53,513+10.3% | Added |
| Geode Capital Management, LLC | 311,354 | $1.22M | 0.00% | +176,190+130.4% | Added |
| State Street Corp | 179,420 | $701.5K | 0.00% | +128,800+254.4% | Added |
| Northern Trust Corp | 130,162 | $508.9K | 0.00% | +70,428+117.9% | Added |
| Ikarian Capital, LLC | 100,000 | $391.0K | 0.06% | +100,000 | New |
| Vanguard Portfolio Management LLC | 88,905 | $347.6K | 0.00% | +88,905 | New |
| Vanguard Fiduciary Trust Co | 88,062 | $344.3K | 0.00% | +18,873+27.3% | Added |
| Alliancebernstein L.P. | 81,280 | $317.8K | 0.00% | +81,280 | New |